ZEVRA THERAPEUTICS, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 09/30/23 | FY 12/31/22 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $106.5M | $23.6M | $27.5M | — | $10.2M |
| Cost of revenue | — | — | $2.9M | — | $222,000 |
| Selling, general & administrative | $77.6M | $54.9M | $34.3M | — | $15.0M |
| Research and development | $12.7M | $42.1M | $39.8M | — | $19.8M |
| Operating income | -$62.9M | -$87.0M | -$49.6M | — | -$42.6M |
| Interest expense | $8.0M | $7.4M | $1.5M | — | $335,000 |
| Pretax income | $86.7M | -$90.1M | -$46.0M | — | -$26.8M |
| Income tax expense | $3.4M | $15.4M | $0 | — | -$33,000 |
| Net income | $83.2M | -$105.5M | -$46.0M | — | -$26.8M |
| Balance Sheet | |||||
| Cash and equivalents | $62.4M | $33.8M | $43.0M | — | $65.5M |
| Current assets | $223.0M | $86.0M | $86.9M | — | $92.8M |
| Total assets | $284.7M | $178.1M | $172.3M | — | $115.3M |
| Current liabilities | $39.3M | $34.1M | $73.7M | — | $12.0M |
| Total liabilities | $130.1M | $138.5M | $110.5M | — | $40.2M |
| Total debt | $63.6M | $61.6M | — | — | — |
| Stockholders' equity | $154.7M | $39.7M | $61.9M | $61.5M | $75.1M |
| Cash Flow Statement | |||||
| Cash from operations | -$1.6M | -$69.7M | -$33.5M | — | -$18.7M |
| Depreciation and amortization | $4.1M | $6.4M | $1.0M | — | $944,000 |
| Stock-based compensation | $12.6M | $14.9M | $6.0M | — | $4.3M |
| Capital expenditure | $835,000 | $0 | $296,000 | — | $93,000 |
| Free cash flow | -$2.4M | -$69.7M | -$33.8M | — | -$18.8M |
| Share repurchases | — | $0 | $3.4M | — | $4.7M |
| Impairments | $0 | $0 | $0 | — | $0 |
Shares outstanding 59.1M · Free float 90.9%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.